Monday, October 05, 2026 5:19 AM ET
3 hours ago
BioMarin reports five-year Pompe disease data showing durable motor function2 days ago
Why Lilly and Novo are betting on amylin to power new obesity drugs after GLP-1s2 days ago
Big Pharma's China deal spree grows with latest tie-up worth up to $7.8 billion2 days ago
De-risking rare disease drug development2 days ago
Micron drops despite 'a great quarter.' Why Cramer is sticking with the stock3 days ago
$942 million: Insurer points finger at AI as suspect hospital charges appear3 days ago
Grindr expands beyond dating with $250 million PurposeMed acquisition3 days ago
Eli Lilly says closely watched combo obesity regimen boosts weight loss in trial4 days ago
Novo's Wegovy pill improves weight loss after people switch from injections4 days ago
White House moves to block $810 million in funding through pocket rescission8 days ago
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s9 days ago
NIH cuts delayed a cancer trial. Patients lost time they didn't have9 days ago
Why we like Starbucks' latest turnaround move — plus, two more wins for Eli Lilly10 days ago
Novo's new strategy hinges on something it can't manufacture: investor trust11 days ago
Trump administration removes around 760,000 Obamacare enrollments11 days ago
Eli Lilly CEO says 700,000 seniors have started GLP-1s after Medicare coverage12 days ago
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo13 days ago
Why more companies are fighting over beauty, health and wellness spending13 days ago
Mitch McConnell returns to Senate after three-month health absence20 days ago
Athletes with autism take center court at the US Open20 days ago
Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' strategy20 days ago
Record U.S. cyclosporiasis outbreak is over, CDC says23 days ago
A rapid-fire update on our 33-stock portfolio, including 6 stocks to buy now23 days ago
Rare disease is taking his vision. A gene therapy could help — if he can get it24 days ago
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead26 days ago
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat26 days ago
AstraZeneca's COPD drug shows late-stage trial wins, boosts blockbuster hopes26 days ago
Pharma major Novartis falls 10% after three drug trial setbacks26 days ago
Cholesterol drug setback casts doubt over multibillion-dollar race27 days ago
Billionaire family offices back healthcare and biotech startups in August1 month ago
Cramer: Here are 3 defensive stock market moves I'm making as oil and rates surge1 month ago